Holen Sie sich die Stockscreener-App
11.65
1.66%
0.19
Handel nachbörslich:
11.66
0.010
+0.09%
Schlusskurs vom Vortag:
$11.46
Offen:
$11.55
24-Stunden-Volumen:
1.17M
Relative Volume:
1.00
Marktkapitalisierung:
$843.17M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-4.81M
KGV:
-23.31
EPS:
-0.4998
Netto-Cashflow:
$-122.54M
1W Leistung:
-2.67%
1M Leistung:
-13.90%
6M Leistung:
+20.98%
1J Leistung:
+268.67%
1-Tages-Spanne:
$11.46
$12.00
1-Wochen-Bereich:
$11.46
$12.55
52-Wochen-Spanne:
$2.95
$17.65
Omeros Corp Stock (OMER) Company Profile
Firmenname
Omeros Corp
Sektor
Branche
Telefon
206-676-5000
Adresse
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Compare OMER vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OMER
Omeros Corp
|
11.65 | 829.42M | 0 | -4.81M | -122.54M | -0.4998 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Omeros Corp Stock (OMER) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-23 | Eingeleitet | D. Boral Capital | Buy |
| 2024-11-14 | Eingeleitet | Rodman & Renshaw | Buy |
| 2022-12-08 | Herabstufung | UBS | Buy → Neutral |
| 2022-11-08 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-06-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-10-01 | Herabstufung | Maxim Group | Buy → Hold |
| 2021-10-01 | Herabstufung | Wedbush | Neutral → Underperform |
| 2021-09-27 | Eingeleitet | JP Morgan | Neutral |
| 2021-02-01 | Eingeleitet | UBS | Buy |
| 2020-10-20 | Eingeleitet | BofA Securities | Buy |
| 2020-08-21 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-14 | Bestätigt | Maxim Group | Buy |
| 2019-05-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-12 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-03-23 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-03-05 | Herabstufung | Needham | Buy → Hold |
| 2017-11-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-05-11 | Herabstufung | Cantor Fitzgerald | Buy → Neutral |
| 2017-03-17 | Bestätigt | Maxim Group | Buy |
| 2017-03-17 | Bestätigt | Needham | Buy |
| 2016-11-16 | Bestätigt | Wedbush | Outperform |
| 2016-11-10 | Bestätigt | Needham | Buy |
| 2016-08-10 | Bestätigt | Maxim Group | Buy |
| 2016-06-03 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2016-03-02 | Bestätigt | Needham | Buy |
| 2016-02-29 | Bestätigt | Wedbush | Outperform |
| 2015-11-11 | Bestätigt | Needham | Buy |
| 2015-08-18 | Bestätigt | WBB Securities | Strong Buy |
| 2015-08-10 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Omeros Corp Aktie (OMER) Neueste Nachrichten
Why did Omeros stock jump 5% in after-hours trading today? - MSN
[144] OMEROS CORP SEC Filing - Stock Titan
OMER Technical Analysis & Stock Price Forecast - Intellectia AI
Omeros gets FDA approval for YARTEMLEA as first therapy for TA-TMA - MSN
Earnings call transcript: Omeros Q1 2026: Stock dips after earnings miss - Investing.com
OMER Stock Price, Quote & Chart | OMEROS CORP (NASDAQ:OMER) - ChartMill
Seattle InnoSEngine headed to Bothell I An update on Omeros - The Business Journals
Omeros Corporation (NASDAQ:OMER) Q1 2026 Earnings Call Transcript - Insider Monkey
Omeros (OMER) Q1 2026 Earnings Transcript - The Globe and Mail
OMER Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
Omeros Corporation Q1 2026 Earnings Call Summary - Yahoo Finance
Omeros (OMER) Reports Strong Q1 2026 Earnings and Positive Cash Flow from YARTEMLEA - GuruFocus
Omeros Corp (OMER) Q1 2026 Earnings Call Highlights: Strong YART - GuruFocus
OMER SWOT Analysis: Key Insights from Q1 2026 10-Q Filing - GuruFocus
Omeros Q1 Earnings Call Highlights - Barchart
How Should Investors Value Omeros (OMER) After Q1 2026 EPS $0.62 - GuruFocus
Omeros (OMER) Reports Q1 Revenue and Highlights Growth Initiativ - GuruFocus
Omeros Q1 2026 Earnings Call Transcript - MarketBeat
Omeros earnings missed by $0.12, revenue fell short of estimates - Investing.com Canada
Earnings call transcript: Omeros misses Q1 2026 expectations, stock dips - Investing.com
Omeros Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Omeros Corp (NASDAQ:OMER) Swings to Profit on YARTEMLEA Launch, Topping EPS Forecasts - ChartMill
OMEROS ($OMER) Releases Q1 2026 Earnings - Quiver Quantitative
Q1 2026 Omeros Corp Earnings Call Transcript - GuruFocus
Omeros: Q1 Earnings Snapshot - Barchart.com
YARTEMLEA launch and zaltenibart deal reshape Omeros (NASDAQ: OMER) - Stock Titan
Omeros (NASDAQ: OMER) turns Q1 profit on YARTEMLEA sales and CMS gains - Stock Titan
New transplant drug gains Medicare billing code, logs $11M sales - Stock Titan
Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026 - BioSpace
TradingKey - TradingKey
Omeros earnings up next as investors eye YARTEMLEA launch By Investing.com - Investing.com South Africa
100% Of This Omeros Insider's Holdings Were Sold - Moomoo
OMER stock on track for best week in nearly 4 months after receiving permanent reimbursement code for treatment - MSN
UBS Group AG Grows Position in Omeros Corporation $OMER - MarketBeat
MSN Money - MSN
Assessing Omeros (OMER) Valuation After Recent Share Price Rebound And Novo Nordisk Deal Prospects - simplywall.st
Omeros Corporation (NASDAQ:OMER) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Omeros (NASDAQ:OMER) Stock Price Crosses Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
OMEROS CORP ($OMER) CEO 2025 Pay Revealed - Quiver Quantitative
Executive pay, incentives and votes detailed in Omeros (NASDAQ: OMER) 2026 proxy - Stock Titan
[ARS] OMEROS CORP SEC Filing - Stock Titan
Omeros rises as Novo deal boosts Q4 earnings - MSN
OMER stock surges 5% after hours on Novo Nordisk deal windfall and drug launch optimism - MSN
Zacks Industry Outlook Highlights Phibro Animal Health, BioLife Solutions, Omeros and Brainsway - Yahoo Finance
Omeros Stock Logs Best Session Ever After HC Wainwright Doubles Target On Novo Nordisk Deal; Retail Sees Big Upside - MSN
Omeros (NASDAQ:OMER) Trading 6.3% HigherShould You Buy? - MarketBeat
Here's Why Omeros (OMER) is a Great Momentum Stock to Buy - Yahoo Finance
Wall Street Analysts Believe Omeros (OMER) Could Rally 222.76%: Here's is How to Trade - Yahoo Finance
Finanzdaten der Omeros Corp-Aktie (OMER)
Umsatz
Nettogewinn
Free Cashflow
ENV
Omeros Corp-Aktie (OMER) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Demopulos Gregory A MD | Chairman, CEO & President |
Feb 18 '26 |
Option Exercise |
10.27 |
400,000 |
4,108,000 |
1,826,986 |
| Borges David J. | VP, Finance & CAO |
Jan 13 '26 |
Option Exercise |
3.06 |
30,000 |
91,800 |
30,000 |
| Borges David J. | VP, Finance & CAO |
Jan 12 '26 |
Sale |
12.72 |
30,000 |
381,600 |
0 |
| Borges David J. | VP, Finance & CAO |
Jan 13 '26 |
Sale |
12.31 |
30,000 |
369,315 |
0 |
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):